← Back to your selection

Alexandria Venture Investments

Activity from announced rounds

Activity in this selectionricardo-villela-marino-34741afb
Rounds participated in
10
Confirmed lead rounds
—
10 roles undisclosed
New companies
10
First participation on record · 0 follow-on
Funding in participating rounds
$635M
10 disclosed · full round size, not this investor’s share

By stage

Series A3
Series B3
Undisclosed3
Series C+1

By primary sector

Biotech9
AI1

By country

United States10

Rounds

10 in this selection
Leal Therapeutics

Develops neuro-metabolic therapeutics for schizophrenia and ALS

$30MSeries A
Role not disclosed
Khartis Therapeutics

Develops oral small molecule therapies for immunological and chronic diseases

$50MSeries B
Role not disclosed
SonoThera

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B
Role not disclosed
CREATE Medicines

Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies

$122MSeries B
Role not disclosed
Fathom Therapeutics

Uses quantum chemistry and AI to design novel drug molecules

$47MSeries A
Role not disclosed
Alloy Therapeutics

Provides AI-powered platforms and integrated services for drug discovery and development

$40MSeries E
Role not disclosed
Ten63 Therapeutics

Develops AI-driven drug discovery platform for first- and best-in-class therapeutics

$45MStrategic
Role not disclosed
TRex Bio

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosed
Role not disclosed
Proxima

Develops AI-driven drug discovery for proximity therapeutics

$80MUndisclosed
Role not disclosed